Evicto
Authorised
This medicine is authorised for use in the European Union
selamectin
MedicineVeterinaryAuthorised
Overview
Evicto is an antiparasitic medicine used to treat and prevent infestations with parasites that live on the skin or in the fur of cats and dogs, such as fleas and mites, as well as treating worms that live inside the body. It is used in the following ways:
- to treat and prevent flea infestations in cats and dogs, by killing adult fleas, their larvae and their eggs on the animal, and in the litters of pregnant or nursing cats or dogs. It can also be used as part of a treatment for flea allergy dermatitis (skin inflammation),
- to prevent heartworm disease in cats and dogs,
- to treat ear mites in cats and dogs,
- to treat adult intestinal roundworms and hookworms in cats,
- to treat adult intestinal roundworms in dogs,
- to treat biting lice infestations in cats and dogs,
- to treat sarcoptic mange (scabies) in dogs.
Evicto contains the active substance selamectin and is a ‘generic medicine’. This means that Evicto contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the European Union (EU) called Stronghold.
The medicine is available as a spot-on solution in 2 different concentrations (6% and 12%) and in tubes of various sizes (15, 30, 45, 60, 120, 240 and 360 mg). It can only be obtained with a prescription. The strength and the amount to use depend on the weight and species of the animal being treated, and the type of parasite. The contents of the tube are squeezed onto the skin after parting the fur at the base of the neck between the shoulder blades. The active substance is absorbed through the skin and has an effect throughout the animal’s body.
For more information about using Evicto, see the package leaflet or contact your veterinarian or pharmacist.
Evicto contains selamectin, which is an antiparasitic medicine that belongs to the ‘avermectin’ class. Selamectin activates special proteins called ‘chloride channels’ on the surface of nerve and muscle cells of the parasite, allowing charged chloride particles to enter nerve cells and disrupting their normal electrical activity. This causes the paralysis or death of the parasites.
Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Stronghold, and do not need to be repeated for Evicto.
As for every medicine, the company provided studies on the quality of Evicto. There was no need for ‘bioequivalence’ studies to investigate whether Evicto is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because the composition of Evicto is comparable to the reference medicine and when applied to the skin the active substance in both products is expected to be absorbed in the same way.
Because Evicto is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.
Safety information has been included in the summary of product characteristics and the package leaflet for Evicto, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers. The precautions are the same as for the reference medicine since Evicto is a generic medicine.
The European Medicines Agency concluded that, in accordance with EU requirements, Evicto has been shown to be comparable to Stronghold. Therefore, the Agency’s view was that, as for Stronghold, the benefit of Evicto outweighs the identified risk and it can be authorised for use in the EU.
Evicto received a marketing authorisation valid throughout the EU on 19 July 2019.
Product information
Latest procedure affecting product information: IG/1409/G
07/10/2021
Product details
- Name of medicine
- Evicto
- Active substance
- selamectin
- International non-proprietary name (INN) or common name
- selamectin
- Species
- Cats
- Dogs
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QP54AA05
Pharmacotherapeutic group
EndectocidesTherapeutic indication
- Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven week of age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in area to which the animal has access.
- Prevention of heartworm disease caused by Dirofilaria immitis with monthly administration. The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning medication with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult D. immitis.
- Treatment of ear mites (Otodectes cynotis).
Cats:
- Treatment of biting lice infestations (Felicola subrostratus)
- Treatment of adult roundworms (Toxocara cati)
- Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Dogs:
- Treatment of biting lice infestations (Trichodectes canis)
- Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
- Treatment of adult intestinal roundworms (Toxocara canis).
News on Evicto
This page was last updated on